■水通道蛋白-4-抗体-血清阳性(AQP4-IgG+)视神经脊髓炎谱系障碍(NMOSD)和髓磷脂少突胶质细胞糖蛋白相关障碍(MOGAD)是复发性神经炎症性疾病,经常导致慢性疼痛。在这两种疾病中,脊髓(SC)通常受到脊髓炎发作的影响。我们假设AQP4-IgG+NMOSD和MOGAD之间的局部SC体积不同,并且疼痛强度与较低的SC体积相关。为了评估SC白质(WM)的变化,灰质(GM),和疼痛强度的患者近期复发(脊髓炎或视神经炎),我们通过纵向成像和临床数据进一步分析了病例系列中的表型.
■这项回顾性研究分析了36名参与者的横截面数据,包括20例AQP4-IgG+NMOSD和16例MOGAD患者。通过简短疼痛清单和疼痛检测问卷对所有患者进行疼痛评估。SCWM的分割,GM,在C2/C3宫颈水平进行了颈索体积(WM+GM的组合体积)。WM%和GM%使用每个患者作为整体的颈索体积来计算。疼痛的存在,疼痛严重程度,和临床残疾被评估和测试与SC节段的关联。此外,纵向数据在一个病例系列中进行了深入剖析,该病例系列包括4例患者,这些患者在1年内两次MRI访视之间发作.
■在AQP4-IgG+NMOSD中,颈髓体积与24h内平均疼痛严重程度(β=-0.62,p=0.009)和日常生活疼痛干扰(β=-0.56,p=0.010)相关.横断面分析显示AQP4-IgG+NMOSD和MOGAD之间无统计学意义的SC体积差异。然而,在AQP4-IgG+NMOSD中,SCWM%随着最后一次攻击时间的增加而趋于降低(β=-0.41,p=0.096)。在MOGAD中未观察到这种趋势。我们的病例系列包括两名AQP4-IgGNMOSD患者,发现SCGM%增加了约2%,两次就诊之间均伴有脊髓炎或视神经炎发作。同时,在MRI访问之间,两名患有脊髓炎发作的MOGAD患者的GM%降低了1-2%。
■在AQP4-IgG+NMOSD中,下颈索体积与疼痛增加有关.此外,两组疾病相关发作患者在MRI访视之间检测到脐带GM变化。区域SCMRI测量用于监测AQP4-IgGNMOSD和MOGAD中的疾病相关脐带病理学。
UNASSIGNED: Aquaporin-4-antibody-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder (MOGAD) are relapsing neuroinflammatory diseases, frequently leading to chronic pain. In both diseases, the spinal cord (SC) is often affected by myelitis attacks. We hypothesized that regional SC volumes differ between AQP4-IgG + NMOSD and MOGAD and that pain intensity is associated with lower SC volumes. To evaluate changes in the SC white matter (WM), gray matter (GM), and pain intensity in patients with recent relapses (myelitis or optic neuritis), we further profiled phenotypes in a case series with longitudinal imaging and clinical data.
UNASSIGNED: Cross-sectional data from 36 participants were analyzed in this retrospective study, including 20 AQP4-IgG + NMOSD and 16 MOGAD patients. Pain assessment was performed in all patients by the Brief Pain Inventory and painDETECT questionnaires. Segmentation of SC WM, GM, cervical cord volumes (combined volume of WM + GM) was performed at the C2/C3 cervical level. WM% and GM% were calculated using the cervical cord volume as a whole per patient. The presence of pain, pain severity, and clinical disability was evaluated and tested for associations with SC segmentations. Additionally, longitudinal data were deeply profiled in a case series of four patients with attacks between two MRI visits within one year.
UNASSIGNED: In AQP4-IgG + NMOSD, cervical cord volume was associated with mean pain severity within 24 h (β = -0.62, p = 0.009) and with daily life pain interference (β = -0.56, p = 0.010). Cross-sectional analysis showed no statistically significant SC volume differences between AQP4-IgG + NMOSD and MOGAD. However, in AQP4-IgG + NMOSD, SC WM% tended to be lower with increasing time from the last attack (β = -0.41, p = 0.096). This tendency was not observed in MOGAD. Our case series including two AQP4-IgG + NMOSD patients revealed SC GM% increased by roughly 2% with either a myelitis or optic neuritis attack between visits. Meanwhile, GM% decreased by 1-2% in two MOGAD patients with a myelitis attack between MRI visits.
UNASSIGNED: In AQP4-IgG + NMOSD, lower cervical cord volume was associated with increased pain. Furthermore, cord GM changes were detected between MRI visits in patients with disease-related attacks in both groups. Regional SC MRI measures are pertinent for monitoring disease-related cord pathology in AQP4-IgG + NMOSD and MOGAD.